Chen and colleagues suggested that GREM1 is a prognostic marker for better survival in patients with pancreatic neuroendocrine tumors (NETs) (Fig. 1E) (Chen et al. 2013). The gene discussed is GREM1; the disease is pancreatic neuroendocrine tumor.